CN101365715B - 基质金属蛋白酶11疫苗 - Google Patents

基质金属蛋白酶11疫苗 Download PDF

Info

Publication number
CN101365715B
CN101365715B CN2006800370642A CN200680037064A CN101365715B CN 101365715 B CN101365715 B CN 101365715B CN 2006800370642 A CN2006800370642 A CN 2006800370642A CN 200680037064 A CN200680037064 A CN 200680037064A CN 101365715 B CN101365715 B CN 101365715B
Authority
CN
China
Prior art keywords
mmp
encoding
polypeptide
ltb
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800370642A
Other languages
English (en)
Chinese (zh)
Other versions
CN101365715A (zh
Inventor
真纳罗·奇利贝托
多马尼科·拉扎罗
费德里卡·莫里
达尼埃洛·佩鲁齐
L·奥里西焦
N·拉莫尼卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of CN101365715A publication Critical patent/CN101365715A/zh
Application granted granted Critical
Publication of CN101365715B publication Critical patent/CN101365715B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2006800370642A 2005-10-07 2006-10-03 基质金属蛋白酶11疫苗 Expired - Fee Related CN101365715B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72449805P 2005-10-07 2005-10-07
US60/724,498 2005-10-07
PCT/EP2006/009536 WO2007042169A2 (en) 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine

Publications (2)

Publication Number Publication Date
CN101365715A CN101365715A (zh) 2009-02-11
CN101365715B true CN101365715B (zh) 2013-03-27

Family

ID=37451271

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800370642A Expired - Fee Related CN101365715B (zh) 2005-10-07 2006-10-03 基质金属蛋白酶11疫苗

Country Status (9)

Country Link
US (2) US8106176B2 (enExample)
EP (1) EP1934246B8 (enExample)
JP (1) JP5361386B2 (enExample)
CN (1) CN101365715B (enExample)
AT (1) ATE521629T1 (enExample)
AU (1) AU2006301582B2 (enExample)
CA (1) CA2623531C (enExample)
ES (1) ES2370040T3 (enExample)
WO (1) WO2007042169A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
WO2010037124A1 (en) 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
KR101882521B1 (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
EP2971013B1 (en) 2013-03-15 2020-08-19 The University Of British Columbia Lipid nanoparticles for transfection and related methods
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
US20190076460A1 (en) * 2017-02-22 2019-03-14 Enyu Ding An mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes
WO2021071976A1 (en) * 2019-10-08 2021-04-15 Exhaura, Ltd. Compositions and methods for ocular therapy
WO2022220603A1 (ko) 2021-04-16 2022-10-20 고려대학교 산학협력단 코로나-19 바이러스 표적 인간 항체
GB202117583D0 (en) * 2021-12-06 2022-01-19 Cambridge Entpr Ltd Protein expression
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO2000065076A2 (en) 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
IL149009A0 (en) 1999-10-08 2002-11-10 Active Biotech Ab Ab5 toxin b subunt mutants with altered chemical conjugation characteristics
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US20040110152A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of matrix metalloproteinase 11 expression
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1675596A4 (en) * 2003-10-10 2009-01-21 Powderject Vaccines Inc METHOD
ATE555127T1 (de) * 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A Noel et al.Demonstration in vivo that stromelysin-3 functions through its proteolytic activity.《Oncogene》.2000,第19卷1605-1612. *
Erxi Wu et al.Stromelysin-3 Suppresses Tumor Cell Apoptosis in a Murine Model.《Journal of Cellular Biochemistry》.2001,第82卷549-555. *
Liezhen Fu et al.A Causative Role of Stromelysin-3 in Extracellular Matrix Remodeling and Epithelial Apoptosis during Intestinal Metamorphosis in Xenopus laevis.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2005,第280卷(第30期),27856-27865. *
Olivia FROMIGUE et al.ACTIVE STROMELYSIN-3 (MMP-11) INCREASES MCF-7 SURVIVAL IN THREE-DIMENSIONAL MATRIGEL CULTURE VIA ACTIVATION OF p42/p44 MAP-KINASE.《Int. J. Cancer》.2003,第106卷355-363. *
SASHKO DAMJANOVSKI et al.Overexpression of Matrix Metalloproteinases Leads to Lethality in Transgenic Xenopus laevis: Implications for Tissue-Dependent Functions of Matrix Metalloproteinases During Late Embryonic Development.《DEVELOPMENTAL DYNAMICS》.2001,第221卷37-47. *

Also Published As

Publication number Publication date
JP5361386B2 (ja) 2013-12-04
CA2623531A1 (en) 2007-04-19
EP1934246B8 (en) 2012-02-08
ES2370040T3 (es) 2011-12-12
CN101365715A (zh) 2009-02-11
JP2009509553A (ja) 2009-03-12
WO2007042169A3 (en) 2007-05-31
CA2623531C (en) 2013-12-10
AU2006301582A1 (en) 2007-04-19
AU2006301582B2 (en) 2011-10-13
US20090155298A1 (en) 2009-06-18
ATE521629T1 (de) 2011-09-15
EP1934246B1 (en) 2011-08-24
US20120177679A1 (en) 2012-07-12
EP1934246A2 (en) 2008-06-25
US8106176B2 (en) 2012-01-31
US8492522B2 (en) 2013-07-23
WO2007042169A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
US8492522B2 (en) Matrix metalloproteinase 11 vaccine
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
KR20050010040A (ko) 면역원성 조성물
PT2155243E (pt) Composição e métodos compreendendo os antigénios klk3, psca ou folh1
CA2555013C (en) Carcinoembryonic antigen fusions and uses thereof
EP2118128B1 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
US8309096B2 (en) Fusion protein
NZ543922A (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
WO2019101062A9 (zh) 重组疫苗及其应用
CN101001869B (zh) 癌胚抗原融合物和其用途
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof
AU2008206463A1 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: MSD ITALY S. P. A.

Free format text: FORMER OWNER: ISTITUTO DI RICERCHE DI BIOLOGYIA MOLECOLARE P.ANGELETTI S.P.A

Effective date: 20140619

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140619

Address after: Rome Italy

Patentee after: MSD Italy S. p. A.

Address before: Italy Pomezia

Patentee before: Angeletti P. Ist Richerche Bio

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327

Termination date: 20181003